Intelligent Bio Solutions Inc (INBS) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Intelligent Bio Solutions Inc's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Intelligent Bio Solutions Inc's ROI in the fourth quarter of 2026?
Intelligent Bio Solutions Inc recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on investment (ROI) of -152.86%.
Within the Healthcare sector 378 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 4060 to 4226.
In the ever-evolving landscape of healthcare technology, Intelligent Bio Solutions Inc. (IBS) emerges as a notable player, striving to innovate within the realm of drug screening solutions. The company s recent collaboration with Pyrotek, a global engineering leader, marks a significant milestone in the adoption of non-invasive drug screening technologies, signaling potential improvements in industrial safety and productivity. Technological Advancement with Pyrotek Intelligent Bio Solutions has introduced its cutting-edge non-invasive drug screening solution to Pyrotek’s extensive industrial operations. This transition promises to minimize downtime and deliver faster, more cost-effective screening results. By implementing this technology, Pyrotek aims to enhance overall safety and productivity within its operations, highlighting the growing adoption of non-invasive technologies in the industry.
In a remarkable step towards enhancing community welfare and employment opportunities, Intelligent Bio Solutions (INBS) has announced a significant partnership with Spirit Group, an Indigenous-owned marketing and consulting agency based in Australia. This collaboration aims to distribute INBS s cutting-edge Intelligent Fingerprinting Drug Testing solution throughout Australia, particularly focusing on supporting Indigenous communities, ensuring a far-reaching positive impact. Redefining Drug Testing with Innovative SolutionsThe Intelligent Fingerprinting Drug Testing solution stands at the forefront of non-invasive testing technology, offering a convenient and accurate alternative to traditional urine and saliva testing methods. The fingerprint-based system allows for immediate results, providing a quick and efficient drug screening option that can be utilized in various settings, including workplaces, schools, and healthcare facilities. This innovative testing approach not only prioritizes user-friendliness but also aligns with the growing demand for privacy-centric solutions in drug testing. By incorporating advanced technology, the Intelligent Fingerprinting system minimizes the discomfort and invasive nature often associated with conventional drug tests, making it a more approachable choice for individuals and organizations alike.
Intelligent Bio Solutions Inc. Reports Impressive Customer Employee Growth and Stock Performance Amid Financial Challenges In a recent announcement, Intelligent Bio Solutions Inc. (NASDAQ: INBS) revealed a remarkable expansion in its customer employee base, with a staggering 118% year-over-year increase. The company, renowned for its innovative non-invasive drug testing technology, now estimates its total number of employees across its customer base to be approximately 1.4 million. This significant growth represents a testament to Intelligent Bio Solutions Inc. s position as a leader in its field. By providing cutting-edge solutions in drug testing technology, the company has evidently garnered significant traction in the market, resulting in a substantial surge in its customer employee count.
Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives New York, June 13, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS), a medical technology company specializing in intelligent, rapid, non-invasive testing solutions, has recently announced the implementation of a strategic reorganization and productivity plan. This comprehensive plan aims to support the company s global growth initiatives and enhance its overall performance. With the healthcare sector experiencing rapid advancements and increasing demand for innovative medical solutions, Intelligent Bio Solutions recognizes the need for a robust strategy to ensure its long-term success. The company s decision to undertake a reorganization plan reflects its commitment to adapt to a changing industry landscape and position itself as a leader in the market.
Intelligent Bio Solutions Inc. (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, has revealed key performance indicators from its operations in the United Kingdom. These indicators have contributed to the company s growth as the drug screening industry continues to battle drug test cheating and seeks simpler, faster, non-invasive, and more cost-effective solutions. During the twelve months ending in the second quarter of 2024, Intelligent Bio Solutions Inc. recorded a cumulative net loss of $-13 million, resulting in a negative return on investment (ROI) of -322.78%. This figure places the company below 332 other healthcare sector companies that had a higher return on investment.
Intelligent Bio Solutions Inc. Achieves Remarkable Revenue Growth and Successful Public Offering, Fueling Advancement in Healthcare Technologies New York, - Intelligent Bio Solutions Inc. (Nasdaq: INBS), a trailblazing medical technology company specializing in intelligent, rapid, and non-invasive testing solutions, has reported impressive unaudited revenue results for its fiscal third quarter and nine-month period, ended March 31, 2024. The year-over-year unaudited revenue soared by 80% for the third quarter and a remarkable 193% for the nine months, showcasing the company s consistent growth trajectory. Moreover, the third quarter witnessed the highest quarterly cartridge sales since the Intelligent Fingerprinting acquisition in 2022. This extraordinary revenue growth can be attributed to Intelligent Bio Solutions Inc. s commitment to technological advancements and innovation in the medical testing industry. The company has consistently delivered cutting-edge solutions that offer rapid and precise results, revolutionizing healthcare practices. With a focus on non-invasive testing methodologies, Intelligent Bio Solutions Inc. has gained significant market recognition and expanded its customer base, resulting in the substantial revenue boost.
Financial Statements
Intelligent Bio Solutions Inc's IV. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
